Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

POSITIVE BIOPHARMA PARTNER REGULATORY PROGRESS AND EARLY SUCCESS IN FOCUSED ULTRASOUND TECHNOLOGY PLATFORM EXPANSION SOLANA BEACH, CA / ACCESS NEWSWIRE / AUGUST 3, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2026. SECOND QUARTER 2026 HIGHLIGHTS REPORTED SECOND QUARTER REVENUE OF $10.9 MILLION, REPRESENTING 18% OVERALL GROWTH, INCLUDING THE RECENTLY ACQUIRED IRRAFLOW PORTFOLIO; BIOLOGICS AND DRUG DELIVERY REVENUE DECLINED 15% IN THE QUARTER, PRIMARILY DUE TO A DECREASE IN PRODUCTS SHIPPED TO BIOPHARMA CUSTOMERS SUPPORTING NEW TRIAL INITIATIONS COMPARED TO THE SECOND QUARTER A YEAR AGO.

CLEARPOINT NEURO REPORTS SECOND QUARTER 2026 RESULTS

RMAT DESIGNATION SUPPORTS AN EXPEDITED FDA DEVELOPMENT AND REVIEW PATHWAY FOR ASPEN'S INVESTIGATIONAL AUTOLOGOUS CELL REPLACEMENT THERAPY FOR PARKINSON'S DISEASE. SOLANA BEACH, CA / ACCESS NEWSWIRE / JULY 31, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY CONGRATULATED ITS PARTNER ASPEN NEUROSCIENCE, INC. ON RECEIVING REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR SASINEPROCEL (ANPD001), ASPEN'S INVESTIGATIONAL AUTOLOGOUS DOPAMINERGIC NEURON CELL REPLACEMENT THERAPY FOR PARKINSON'S DISEASE.

CLEARPOINT NEURO CONGRATULATES PARTNER ASPEN NEUROSCIENCE ON FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR SASINEPROCEL

SOLANA BEACH, CA / ACCESS NEWSWIRE / JULY 21, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR ITS 2026 SECOND QUARTER ON MONDAY, AUGUST 3RD, AFTER THE MARKET CLOSE. INVESTORS AND ANALYSTS ARE INVITED TO LISTEN TO THE LIVE BROADCAST REVIEW OF THE COMPANY'S 2026 SECOND QUARTER ON MONDAY, AUGUST 3RD AT 4:30 P.M.

CLEARPOINT NEURO TO ANNOUNCE SECOND QUARTER 2026 RESULTS AUGUST 3, 2026

ANNOUNCEMENT IS MADE AFTER SUCCESSFUL PROOF-OF-CONCEPT TRIAL IN A PRECLINICAL MODEL OF INTRAVENOUS DELIVERY OF LARGE MOLECULE TRACERS ACROSS THE BLOOD-BRAIN BARRIER GUIDED BY PROTOTYPE SYSTEMS, INCLUDING BOTH FOCUSED ULTRASOUND HARDWARE AND CLEARPOINT NAVIGATION SOFTWARE AND ROBOTICS SOLANA BEACH, CA / ACCESS NEWSWIRE / MAY 27, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) ("COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED PLANS TO ENTER THE FOCUSED ULTRASOUND MARKET, AND DEMONSTRATED SUCCESSFUL INTRAVENOUS DELIVERY OF TRACERS ACROSS THE BLOOD-BRAIN BARRIER IN A PRECLINICAL MODEL USING THE CLEARPOINT PROTOTYPE SYSTEM. THIS DEVICE WAS BUILT IN PARTNERSHIP WITH THE SONOCARELAB, AT SUNGKYUNKWAN UNIVERSITY IN SUWON, SOUTH KOREA ON THE NATURAL SCIENCE CAMPUS.

CLEARPOINT NEURO ENTERS INTO 10-YEAR FOCUSED ULTRASOUND DEVELOPMENT PARTNERSHIP WITH SUNGKYUNKWAN UNIVERSITY, SOUTH KOREA, FURTHER EXPANDING OUR DRUG DELIVERY ECOSYSTEM AND GLOBAL FOOTPRINT

RECORD REVENUE ACHIEVED INCLUDING 25% ORGANIC GROWTH IN DEVICES AND 43% OVERALL GROWTH SOLANA BEACH, CA / ACCESS NEWSWIRE / MAY 13, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FIRST QUARTER ENDED MARCH 31, 2026. FIRST QUARTER 2026 HIGHLIGHTS REPORTED FIRST QUARTER REVENUE OF $12.1 MILLION, INCLUDING $2.3 MILLION OF IRRAFLOW REVENUE, REPRESENTING 43% OVERALL GROWTH AND 16% YEAR-OVER-YEAR TOTAL ORGANIC GROWTH COMPARED WITH THE FIRST QUARTER OF 2025; THE ACTIVATED INSTALLED BASE ACROSS ALL CLEARPOINT TECHNOLOGY INCLUDING IRRAFLOW SYSTEMS NOW INCLUDES OVER 175 GLOBAL CENTERS; ACHIEVEMENT OF MEASURABLE REVENUE AND COST SYNERGIES THROUGH THE CONTINUING INTEGRATION OF THE IRRAFLOW PRODUCT PORTFOLIO AND TEAM; CONTINUED CLINICAL TRIAL AND REGULATORY PROGRESS ACROSS MORE THAN 60 ACTIVE BIOPHARMA PARTNERS; FDA CLEARANCE AND SUCCESSFUL COMPLETION OF THE FIRST CLINICAL PROCEDURE UTILIZING THE VELOCITY ALPHA MR HIGH SPEED SURGICAL DRILL SYSTEM; RECEIVED MEDICAL DEVICE LICENSE (MDL) FROM HEALTH CANADA FOR THE CLEARPOINT NEURO NAVIGATION SYSTEM, COVERING BOTH MRI-GUIDANCE AND ICT GUIDANCE WORKFLOWS WITH FIRST CASES NOW SCHEDULED; COMPLETION OF THE FIRST COMMERCIAL DRUG DELIVERY CASE UTILIZING CLEARPOINT TECHNOLOGY IN THE ASIA-PACIFIC REGION; GROSS MARGIN EXPANDED TO 64%; AND REPORTED CASH AND CASH EQUIVALENTS TOTALING $35.6 MILLION AS OF MARCH 31, 2026.

CLEARPOINT NEURO REPORTS FIRST QUARTER 2026 RESULTS

SOLANA BEACH, CA / ACCESS NEWSWIRE / MAY 13, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) ("COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT THE VELOCITY ALPHA  MR HIGH SPEED SURGICAL DRILL SYSTEM HAS RECEIVED CE MARKING IN ADDITION TO THE EXISTING FDA 510(K) CLEARANCE IN THE UNITED STATES. THE VELOCITY ALPHA MR HIGH SPEED SURGICAL DRILL SYSTEM IS MANUFACTURED BY GERMAN-BASED SURGICAL EQUIPMENT LEADER ADEOR MEDICAL AG.

CLEARPOINT NEURO ANNOUNCES CE MARKING OF VELOCITY ALPHA MR HIGH SPEED SURGICAL DRILL SYSTEM, FURTHER EXPANDING DRUG DELIVERY ECOSYSTEM AND GLOBAL FOOTPRINT

SOLANA BEACH, CA / ACCESS NEWSWIRE / APRIL 29, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR ITS 2026 FIRST QUARTER ON WEDNESDAY, MAY 13TH, AFTER THE MARKET CLOSE. INVESTORS AND ANALYSTS ARE INVITED TO LISTEN TO THE LIVE BROADCAST REVIEW OF THE COMPANY'S 2026 FIRST QUARTER RESULTS ON WEDNESDAY, MAY 13TH, AT 4:30 P.M.

CLEARPOINT NEURO TO ANNOUNCE FIRST QUARTER 2026 RESULTS MAY 13, 2026

SOLANA BEACH, CA / ACCESS NEWSWIRE / APRIL 22, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) ("COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF THE FIRST CLINICAL PROCEDURE UTILIZING THE 510(K)-CLEARED VELOCITY ALPHA MR HIGH SPEED SURGICAL DRILL SYSTEM. UTILIZED IN A FOUR-TRAJECTORY CLINICAL TRIAL PROCEDURE, THE SYSTEM HIGHLIGHTS ITS SCALABILITY AND POTENTIAL TO SUPPORT A BROADER RANGE OF PROGRAMS WITHIN THE COMPANY'S PARTNERED BIOLOGICS PORTFOLIO.

CLEARPOINT NEURO ANNOUNCES FDA CLEARANCE OF THE VELOCITY ALPHA(R) MR HIGH SPEED SURGICAL DRILL SYSTEM AND FIRST CLINICAL USE, FURTHER EXPANDING OUR DRUG DELIVERY ECOSYSTEM AND GLOBAL FOOTPRINT

COMBINED CLEARANCE OF THE NAVIGATION AND DRUG DELIVERY TECHNOLOGIES ENABLES CANADIAN NEUROSURGERY CENTERS TO LEVERAGE THE COMPANY'S FLAGSHIP IMAGE-GUIDANCE WORKFLOW AND ADVANCES CLEARPOINT NEURO'S OVERALL GLOBAL INFRASTRUCTURE IN SUPPORT OF ITS STRATEGY TO ENABLE 20,000 CELL AND GENE THERAPY PROCEDURES ANNUALLY. SOLANA BEACH, CA / ACCESS NEWSWIRE / APRIL 20, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) ("COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED RECEIPT OF A MEDICAL DEVICE LICENSE (MDL) FROM HEALTH CANADA FOR ITS NEURO NAVIGATION SYSTEM, FURTHER EXPANDING OUR DRUG DELIVERY ECOSYSTEM AND GLOBAL FOOTPRINT.

CLEARPOINT NEURO ANNOUNCES CANADIAN APPROVAL FOR ITS NAVIGATION SYSTEM FURTHER EXPANDING OUR DRUG DELIVERY ECOSYSTEM AND GLOBAL FOOTPRINT

RECORD REVENUE AND IRRAS HOLDINGS ACQUISITION HIGHLIGHT THE COMPANY'S 'FAST. FORWARD.' STRATEGY SOLANA BEACH, CA / ACCESS NEWSWIRE / MARCH 17, 2026 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025.

ClearPoint Neuro, Inc.

CLPT

Price

Financial Reports

No items found.

Press Releases

ClearPoint Neuro, Inc.

CLPT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CLPT